Support the INSULIN Act to get biosimilar insulin to market more quickly.

Diana DeGette · Colorado · Democratic

policy impact 0.60 specificity 0.60 extraction confidence 76%

Commitment kind: outcome. Promised action: Support the INSULIN Act's provisions to accelerate biosimilar insulin availability.. Promised outcome: Biosimilar insulin reaches the market more quickly.. Deadline: unknown; not assumed expired. U.S. Representative Diana DeGette press release on introducing the INSULIN Act in the 119th Congress.

Occurrences

The INSULIN Act will: Cap out-of-pocket patient cost-sharing for individuals with insurance at $35 a month; Prohibit health care plans from applying any deductible to select insulin products; Help uninsured people with diabetes get access to insulin; and Get biosimilar insulin to market more quickly.

The press release says the INSULIN Act will speed biosimilar insulin's path to market.

DeGette Delivers Bill to Cap Insulin Cost at $35 Per Month | Congresswoman Diana DeGette
primary · press_release · model gpt-5.5

Full Title To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.

The bill DeGette introduced seeks to reduce insulin prices, consistent with the existing INSULIN Act commitment to accelerate biosimilar insulin availability.

H.R. 10227 (IH) - Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 - BILLS-119hr10227ih | Content Details | GovInfo
primary · other · model gpt-5.5

Evidence

verified · Source version 65808 · locator 2040

Sponsors Diana DeGette(CO)

Fetched verbatim passage. AI summary (separate from source): GovInfo identifies Diana DeGette as the sponsor of H.R. 10227, the House INSULIN Act of 2026, introduced during the lookback window.

unresolved same_term A for effort

H.R. 10227 (IH) - Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 - BILLS-119hr10227ih | Content Details | GovInfo
primary · model gpt-5.5 · confidence 95%

unverified · Source version 52814 · locator unknown

SEC. 6. EXPEDITING BIOSIMILAR COMPETITION.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The introduced House bill contains a section aimed at speeding biosimilar competition, matching the commitment's policy mechanism.

unresolved same_term A for effort

H.R. 10227 Introduced in House Text - INSULIN Act of 2026 - GovInfo
secondary · model gpt-5.5 · confidence 93%

verified · Source version 65808 · locator 1298

Last Action Date Listed September 2, 2026

Fetched verbatim passage. AI summary (separate from source): GovInfo's latest listed House action is the September 2, 2026 referral/introductory action, with no enactment shown as of the refresh date, so the legislative outcome remains unresolved.

unresolved same_term

H.R. 10227 (IH) - Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 - BILLS-119hr10227ih | Content Details | GovInfo
primary · model gpt-5.5 · confidence 91%

verified · Source version 52809 · locator 4358

Get biosimilar insulin to market more quickly.

Fetched verbatim passage. AI summary (separate from source): DeGette's official House press release says the INSULIN Act would get biosimilar insulin to market more quickly, confirming the claimed goal and her active support through introduction.

unresolved same_term A for effort

DeGette Delivers Bill to Cap Insulin Cost at $35 Per Month | Congresswoman Diana DeGette
primary · model gpt-5.5 · confidence 90%

Assessments

Public state: unverified As of unknown · unverified · Source revision or retrieval eligibility changed; current packet requires reassessment.. Original AI recommendation (not independently established): unresolved. unknown

provider integrity · model deterministic · confidence 0%

Public state: pending As of 2026-09-14 · verified · . Original AI recommendation (not independently established): unresolved. unknown A for effort

The verified commitment promised the INSULIN Act would get biosimilar insulin to market more quickly. Verified evidence shows Diana DeGette sponsored the bill, which supports material effort, but the only verified legislative status evidence shows a last listed action date of September 2, 2026 and does not show enactment or a documented market outcome. Because this was an outcome promise and no deadline has expired as of 2026-09-14, introduction/sponsorship alone does not fulfill it.

provider codex_cli · model gpt-5.5 · confidence 91%